Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association
Keros Therapeutics will be hosting a conference call and webcast today, June 10, 2022, at 8:00 a.m. Eastern time.
LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc.